Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping

Abstract

Clinical heterogeneity represents a great challenge for cancer therapeutics. Molecular classification of patients into different subtypes based on genetic or epigenetic characteristics has the potential to revolutionize the clinical care and mechanistic understanding of a wide spectrum of cancers, including endometrial carcinoma, the most common gynecological cancer affecting women.

Keywords:

• cancer therapeutics
• CTNNB1 mutation
• endometrial carcinoma
• molecular subtyping
• wnt signaling pathway

Financial & competing interests disclosure

This study was partially supported by a Career Development Award from MD Anderson Gynecologic SPORE in Uterine Cancers (NIH 2P50 CA098258-08 to Y Liu), funding for the Genome Data Analysis Centers from the National Institutes of Health (U24 CA143835 to W Zhang), and funding for the Cancer Systems Informatics Center from the National Foundation for Cancer Research (W Zhang). The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.